Sakar Healthcare Ltd (SAKAR) AI Stock Analysis

• Market Cap: ₹7.26B
• Dividend Yield: N/A
• Average Volume (3M): 13.54K
• Price to Earnings (P/E): 36.3
• Beta (1Y): 0.49
• Revenue Growth: 21.65%
• EPS Growth: 73.84%
• Country: IN
• Employees: 325
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.11
• Shares Outstanding: 21,949,910
• 10 Day Avg. Volume: 6,445
• 30 Day Avg. Volume: 13,542
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹375.00
• Price Target Upside: 14.09% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: ₹375.00 ▲(14.09% Upside)

Sakar Healthcare Ltd's stock is supported by strong financial performance, particularly in revenue growth and operational efficiency. Technical analysis indicates a positive trend, but the high P/E ratio suggests the stock may be overvalued. Absence of earnings call and corporate events data limits the assessment.

Sakar Healthcare Ltd Business Overview & Revenue Model

Company Description

Sakar Healthcare Ltd (SAKAR) is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in the healthcare sector, focusing on the production of injectable formulations, oral solids, oral liquids, and other pharmaceutical products. Sakar Healthcare is committed to providing quality healthcare solutions and has a presence in both domestic and international markets.

How the Company Makes Money

Sakar Healthcare Ltd makes money through the sale of its pharmaceutical products, which include a variety of formulations such as injectables, tablets, capsules, and liquid orals. The company generates revenue by supplying these products to hospitals, clinics, pharmacies, and other healthcare facilities in domestic and international markets. Additionally, Sakar Healthcare engages in contract manufacturing, producing pharmaceutical products for other companies, which serves as an additional revenue stream. The company may also have strategic partnerships or collaborations with other pharmaceutical companies, which can enhance its market reach and contribute to its overall earnings.

Sakar Healthcare Ltd Financial Statement Overview

Summary

Sakar Healthcare Ltd shows strong revenue growth and improved operational efficiency with increasing EBIT margins. The balance sheet indicates a better debt position and stable equity. However, challenges in maintaining consistent profitability and managing cash flow effectively persist.

Income Statement

Sakar Healthcare Ltd has demonstrated a consistent increase in revenue over the years, with a notable revenue growth rate of 15.2% in 2025 compared to 2024, and 15.6% from 2024 to 2023. The Gross Profit Margin has been fluctuating but remained strong, standing at 24.1% for 2025. However, the Net Profit Margin has been lower at 9.9% for 2025, indicating higher operating costs or expenses. The EBIT margin improved to 16.2% in 2025 from 12.9% in 2024, showing operational efficiency. Nonetheless, the drop in Gross Profit Margin from 45.3% in 2024 to 24.1% in 2025 is a concern.

Balance Sheet

The company's Debt-to-Equity ratio has improved, decreasing from 0.30 in 2024 to 0.26 in 2025, indicating a reduction in leverage. The Return on Equity (ROE) has been stable, with 6.1% in 2025, showcasing moderate profitability relative to equity. The Equity Ratio stood at 68.8% in 2025, reflecting a strong equity position. Despite the positive trends, the ratio of Total Debt to Stockholders' Equity remains notable, requiring careful monitoring.

Cash Flow

The Free Cash Flow has been negative but shows signs of improvement, with a 61.4% increase in 2025 compared to 2024. The Operating Cash Flow to Net Income ratio was strong at 1.07 in 2025, indicating that the company is efficiently converting its net income into cash. However, the Free Cash Flow to Net Income ratio remains negative, suggesting challenges in covering capital expenditures solely through operational earnings.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2021	Mar 2022
Income Statement
Total Revenue	1.78B	1.54B	1.33B	947.39M	1.28B
Gross Profit	427.91M	699.59M	598.12M	432.46M	534.12M
EBITDA	509.44M	393.27M	341.03M	237.73M	315.72M
Net Income	175.02M	116.71M	127.59M	106.83M	152.43M
Balance Sheet
Total Assets	4.15B	3.95B	3.36B	1.78B	2.68B
Cash, Cash Equivalents and Short-Term Investments	3.09M	4.66M	35.23M	824.65K	71.36M
Total Debt	749.55M	793.52M	1.11B	425.97M	928.62M
Total Liabilities	1.30B	1.33B	1.63B	793.40M	1.40B
Stockholders Equity	2.85B	2.62B	1.73B	984.52M	1.27B
Cash Flow
Free Cash Flow	-135.52M	-350.93M	-468.81M	-209.69M	-618.33M
Operating Cash Flow	187.31M	244.67M	353.14M	145.77M	356.99M
Investing Cash Flow	-307.09M	-515.39M	-743.77M	-468.33M	-903.72M
Financing Cash Flow	118.22M	274.45M	410.96M	320.33M	546.21M

Sakar Healthcare Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 328.70
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Neutral. The current price of 328.7 is below the 20-day moving average (MA) of 348.68, below the 50-day MA of 343.42, and above the 200-day MA of 299.22, indicating a neutral trend. The MACD of -4.04 indicates Positive momentum. The RSI at 34.99 is Neutral, neither overbought nor oversold. The STOCH value of 15.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SAKAR.

Sakar Healthcare Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹6.31B	11.99		―	9.15%	88.32%
SAKAR	68 Neutral	₹7.26B	36.27		―	21.65%	73.84%
KILITCH	65 Neutral	₹7.87B	27.53		―	28.47%	78.96%
MEDICAMEQ	54 Neutral	₹4.83B	51.18		0.28%	-9.35%	-17.40%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
NECLIFE	43 Neutral	₹3.46B	30.02		―	-0.74%	-2375.84%

Sakar Healthcare Ltd Corporate Events

Sakar Healthcare Ltd Confirms Compliance with SEBI Regulations for Q2 2025

Sakar Healthcare Ltd has submitted a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending June 30, 2025. This announcement confirms the dematerialization of securities and their listing on stock exchanges, ensuring compliance with regulatory requirements and maintaining transparency for stakeholders.